Table 1.
Chromatin marks | Transcription factors | Method | Cell type | Reference |
---|---|---|---|---|
Acetylation | ||||
H3K9ac, H3K14ac, H4panAc | ERG, FLI1, CBFB, HEB, RUNX1, ETO, AML1-ETO, RNAPII | ChIP-Seq | Cell lines, patient t(8;21) AML blasts and normal CD34+ hematopoietic cells | Martens et al. [66] |
H3ac | AML1/ETO, AML1, LMO2, Pol II, Pu.1, C/EBPα, HDAC2, P300 | ChIP-Seq DNAseI Footprinting | Cell lines, primary cells, normal. CD34+ | Ptasinska et al. [58] |
H3K9ac | AML1/ETO, AML1, Pol II | ChIP-Seq DNAse I hypersensitivity | Primary cells and cell lines | Ptasinska et al. [67] |
H3K27ac | AML1/ETO | ChIP-Seq DNAse I hypersensitivity | Cell lines, primary AML cells, AML1/ETO-transduced iPSCs | Mandoli et al. [70] |
H2A.Zac | AML1/ETO, P300 | Nuclease accessibility coupled with high-throughput sequencing (NA-seq) and ChIP-seq | Cell lines and primary patient blasts | Saeed et al. [69] |
K43ac | AML1/ETO, P300 | ChIP-Seq | Cell lines | Wang et al. [36] |
H3K9/14ac | AML1/ETO9a, PRMT1 | ChIP-qPCR | Cell lines | Shia et al. [39] |
H4ac loss | AML1/ETO, SP1 | ChIP-chip analysis | Transduced human HSPCs | Maiques-Diaz [118] |
Methylation | ||||
H3K4me3, H3K4me1, H3K36me3, H3K27me3, H3K9me3 | AML1/ETO | ChIP-seq, DNA hypersensitivity | Cell lines, primary AML cells, AML1/ETO-transduced iPSCs | Mandoli et al. [70] |
H3K4me3, H3K27me3 | AML1, NCoR, P300 | ChIP-Seq | Cell lines | Trombly et al. [72] |
H4R3me2a | AML1/ETO9a, PRMT1 | ChIP-qPCR | Cell lines | Shia et al. [39] |
H3K4me3 | AML1, AML1/ETO and HEB | ChIP-qPCR | Cell lines | Gardini et al. [73] |
K43me | AML1/ETO, EZH1 | ChIP-Seq | Cell lines | Dou et al. [38] |
The chromatin marks in Wang and Dou et al. refer to site-specific lysine acetylation/methylation of the respective target protein.